Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGIME: Darbepoetin alpha +/- filgrastim in low-risk MDS
NCT01196715Phase 3Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Nov 2010
- Primary completion
- Oct 2015
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
A Phase 3 trial of darbepoetin alfa in myelodysplastic syndrome (MDS), sponsored by Barts Health NHS Trust. Started Nov 2010; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01196715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01196715.